Zorevunersen (STK-001) FAQs: Spotlight on the Upcoming Phase 3 Studies
This is an exciting time for the Dravet syndrome community. The first potentially disease-modifying treatment targeting the genetic cause of Dravet syndrome has completed initial human studies and is now advancing to a pivotal global Phase 3 trial. If the study confirms that this therapy is safe and effective, the next step will be seeking […]
Zorevunersen (STK-001) FAQs: Spotlight on the Upcoming Phase 3 Studies Read More »